Angioimmunoblastic T-cell lymphoma is an aggressive peripheral T-cell lymphoma whose natural history is not fully understood. It accounts for 1-2% of all non-Hodgkin's lymphoma. 1, 2 Patients present with generalized lymphadenopathy (up to 90%), hepatosplenomegaly (50-79%), cutaneous rash (50%), hypergammaglobulinaemia (50%), B-symptoms (70%), pleural effusion (37%) and autoimmune phenomena (20%). 3, 4 More than 75% of patients are clinical stages III-IV at diagnosis and despite aggressive therapies their median survival is less than 3 years. 3, 5 Histologically the majority of cases show regressed follicles, a polymorphous infiltrate of medium-sized lymphocytes with mild cytological atypia, Epstein-Barr virus (EBV)-positive large B blasts and, characteristically, expanded follicular dendritic cell meshworks encircling high endothelial venules. 1 However rare cases can present with hyperplastic germinal centres and this pattern has been frequently misdiagnosed as reactive hyperplasia. 3, 6 The natural history and frequency of these cases, also known as pattern I, is poorly documented with only small series and a few case reports. [7] [8] [9] [10] It remains to be determined whether patients with angioimmunoblastic T-cell lymphoma -(pattern I) have a similar or different clinical presentation and behaviour to classical angioimmunoblastic T-cell lymphoma. Furthermore little is known of the histologic progression of angioimmunoblastic T-cell lymphoma in consecutive biopsies and whether this progression has any clinical significance.
Recent gene-expression profiling studies have suggested that T FH (follicular helper T cells) may be the cell of origin of Angioimmunoblastic T-cell lymphoma. 11, 12 T FH cells are CXCR5 þ /CCR7À T cells, located in germinal centres, which provide help to B cells in cellular immune responses, through the acquisition of other molecules such as ICOS (immune costimulatory molecule), CD40L and IL-21. 13 Among the genes upregulated in T FH cells are CXCL13, BCL6 and programmed death-1 (PD1) 14 and these molecules can be detected by immunohistological staining of paraffin sections. PD1 and CXCL13 are particularly useful markers in the diagnosis of Angioimmunoblastic T-cell lymphoma, helping to differentiate this condition from lymphoid hyperplasias and peripheral T-cell lymphoma unspecified (PTCL-u). [15] [16] [17] [18] [19] [20] Animal studies have shown that germinal centres have three compartments: the dark zone, the light zone and the 'outer zone', the latter being rich in CD4 þ CXCR5 þ CD57 À T FH cells. 21 In addition T FH appear to express high levels of the 'inducible costimulatory' (ICOS) molecule, a CD28 homologue implicated in the regulation of T-cell differentiation. It has recently been proposed that ICOS may be dysregulated in angioimmunoblastic T-cell lymphomas. 22 Preliminary studies with ICOS in paraffin sections have shown a similar staining pattern to PD1. The majority of ICOS þ T cells also express PD1 and Bcl6. Angioimmunoblastic T-cell lymphoma (51/52) and 18/18 follicular variant of peripheral T-cell lymphoma have also been shown to be positive with ICOS (Marafioti T (2008), manuscript in preparation).
In view of the difficulty in distinguishing Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres (pattern I) from reactive follicular hyperplasias on morphological criteria alone, we undertook this study with the aim of analysing the expression of T FH markers (PD1, CXCL13 and ICOS) in 10 cases of Angioimmunoblastic T-cell lymphoma pattern I. Morphological, immunohistochemical and clinical features of this Angioimmunoblastic T-cell lymphoma subgroup were also analysed.
Materials and methods

Tissue Samples
We reviewed a group of 88 consecutive nodal Angioimmunoblastic T-cell lymphoma cases submitted for diagnosis or second opinion to University College London Hospital and the Spanish National Cancer Institute (CNIO, Pathology Laboratory) between 1998 and 2007. Ten cases were classified as Angioimmunoblastic T-cell lymphoma (pattern I)/ hyperplastic germinal centres. Criteria for the diagnosis were based on WHO recommendations 1 and previous studies, 7, 9 including hyperplastic follicles, a polymorphous infiltrate composed of medium-sized lymphocytes, transformed large blasts, plasma cells, macrophages and eosinophils, associated with prominent vascularity in the paracortex and/or a subtle expansion of the follicular dentritic cell meshwork. Twenty-one 21 lymph nodes with reactive follicular hyperplasia (including four cases of HIV associated lymphadenopathy) were included as controls and the staining pattern of CXCL13, PD1 and ICOS was examined in both the reactive nodes and Angioimmunoblastic T-cell lymphoma pattern I cases. The use of archival tissues was approved by the local research ethics committees of the authors' institutions.
Immunohistochemistry
Immunohistochemical staining of tissue sections was performed using the EnVision staining system 23 with a heat-induced antigen-retrieval step. Sections were immersed in boiling 10 mM sodium citrate at pH 6.5 for 2 min in a pressure cooker. Each case was stained with a panel of 11 different antibodies (Table 1) including the new, but well-recognized T FH cell markers such as CXCL-13, PD1 and ICOS. Reactive tonsil was used as control. The primary antibodies were omitted to provide negative controls. For CXCL-13, PD1 and ICOS expression, the percentage of neoplastic cells was scored as follows: À, no evidence of positivity; þ , 5-15% positive neoplastic cells; þ þ , 15-40% positive neoplastic cells and þ þ þ , more than 40% positive neoplastic cells.
In Situ Hybiridization for EBV-Encoded RNA
The presence of EBV RNA was analysed by nonisotopic in situ hybridization with EBV-encoded RNA (EBER) 1 and 2 oligonucleotide probes (Dakocytomation) on paraffin-embedded tissue sections, as previously described. 
Results
Clinical Features
Clinical details are summarized in Table 2 . There were seven men and three women who were between the ages of 34 and 105 years at presentation. Eight of nine cases (where staging information was available) presented with disseminated disease (stages III-IV). Extranodal involvement was present in 6 patients (66.7%), most frequently lung, bone marrow, liver, skin and central nervous system, in 22% (2/9), 22% (2/9), 11% (1/9), 11% (1/9) and 11% (1/9). Organomegaly (hepato or splenomegaly) was present in three patients (33%), three patients (33%) had haemolytic autoimmune anaemia and one patient (11%) had polyclonal gammapathy. The International Prognostic Index (IPI) was recorded in seven patients: five (71%) patients were classified as low risk (0-1) and two (29%) as intermediatehigh risk (IPI 3). Follow-up was available in nine cases and after a median follow-up of 37 months (range 16-68 months) seven patients (78%) were still alive and four (44%) achieved complete remission with no evidence of recurrent disease. Two patients (22%) died of the disease.
Histology, Immunohistochemistry and Molecular Studies (Table 3) Histologically, all 10 cases showed hyperplastic germinal centres with a few tingible-body macrophages and indistinct mantle zones. There was expansion of the interfollicular area by a polymorphic infiltrate composed of medium-sized lymphocytes, immunoblasts, plasma cells, eosinophils and high-endothelial postcapillary venules. Scattered clusters of clear cells were seen in three cases. In eight cases, there was a subtle expansion of follicular dendritic cells (FDC) highlighted with CD21/23 but no large accumulations of FDC encircling high-endothelial veins were detected.
All 10 cases were positive for both PD1 (membrane) and CXCL13 (cytoplasmic and sometimes dot-like reinforcement) markers but the percentage and strength of staining of positive cells was more intense with PD1 than CXCL13. Interestingly, PD1 showed a strong 'perifollicular' pattern with aggregates of positive cells in the outer zone of the germinal centre and also highlighted clusters of neoplastic cells around high endothelial venules. Eight cases stained with ICOS showed similar strong perifollicular pattern and also demonstrated clusters of neoplastic cells in interfollicular areas (Figure 1 ).
Neoplastic cells were CD3 þ /CD4 þ /CD8À in 10/ 10 cases (100%). CD10 þ cells typically accounted for 5-10% of CD3 þ cells and represented a smaller subset of CD3 þ cells than PD1 þ cells (440% of neoplastic cells in 60% of cases). EBER þ B-blasts were present in 9/9 cases (100%).
In reactive follicular hyperplasias PD1, CXCL13 and ICOS were expressed by a few cells in germinal centres and a few T cells in interfollicular areas (weak staining; Figure 2 ) but no other morphological features of Angioimmunoblastic T-cell lymphoma were present in these cases. PCR studies of both IgH and TCR gene rearrangement were informative in three and five cases, respectively. IgH clonal rearrangement was present in one case (case 7) and monoclonal TCR rearrangement was detected in two patients (cases 1 and 2).
In two patients, whose initial biopsy showed Angioimmunoblastic T-cell lymphoma (pattern I) (cases 2 and 5), consecutive biopsies (11 and 24 months after initial diagnosis) showed typical features of Angioimmunoblastic T-cell lymphoma (pattern II) with a polymorphic infiltrate, expanded meshwork of FDC surrounding vessels and prominent high endothelial venules. PD1 in these two cases highlighted increased number of neoplastic cells distributed around expanded FDC meshworks (Figure 3 ).
Discussion
The diagnostic criteria for Angioimmunoblastic T-cell lymphoma, as defined by Dogan et al, 1 only apply to typical (pattern II/III) cases but in a significant proportion of cases (up to 17%) 3,26 the morphological findings mimic reactive follicular hyperplasia. The histological architecture of Angioimmunoblastic T-cell lymphoma with pattern I is characterized by largely preserved lymph node architecture, hyperplastic B-cell follicles surrounded by expanded paracortex containing a polymorphic infiltrate of lymphocytes, transformed large lymphoid blasts, plasma cells, macrophages and eosinophils with a prominent vascular network and little or no evidence of follicular dendritic cells expansion. 6 Early reports suggested that germinal centres with irregular borders and abundant tingible body macrophages in interfollicular areas were characteristic of pattern I Angioimmunoblastic T-cell lymphoma 9 but these criteria are not reproducible and a correct diagnosis cannot always be achieved based on morphological findings alone. Our data corroborate previous studies 18 showing that expression of PD1 and CXLC13 in non-neoplastic lymph nodes and reactive follicular hyperplasias is confined to a few T cells in germinal centres and scattered T cells in interfollicular areas (usually weak). In addition we have shown that in pattern I Angioimmunoblastic T-cell lymphoma, T FH cell markers, particularly PD1, highlight clusters of neoplastic cells in 'perifollicular' areas and around high endothelial venules in the expanded paracortex. This 'perifollicular' pattern of neoplastic cells was also recorded in 3/29 cases reported by Dupuis et al 17 with CXCL13 antibody staining. In our experience, the presence and pattern of distribution of PD1 þ T cells and EBER þ B blasts (90% in our series) is very helpful in distinguishing Angioimmunoblastic T-cell lymphoma pattern I from reactive hyperplasias. We have shown that PD1 has a diagnostic utility in the diagnosis of Angioimmunoblastic T-cell lymphoma, but it should be pointed out that expression of PD1 has also been reported in a small group of PTCL-u, diffuse large B-cell lymphomas 18 and very recently in small lymphocytic lymphoma (SLL) and grade III follicular lymphoma. 27 Our results are in accordance with preliminary results by Marafioti-T (data presented at the Groupe d'Etudes des Lymphomes de l'Adulte (GELA) meeting 2008, manuscript in preparation), showing that ICOS is a useful marker in the diagnosis of Angioimmunoblastic T-cell lymphoma and provides further evidence to support the derivation of Angioimmunoblastic T-cell lymphoma from T FH cells.
Although CD10 has been proposed as an immunophenotypic marker of neoplastic T cells in Angioimmunoblastic T-cell lymphoma in up to 90% of cases, 6 we found that only a small proportion of neoplastic T cells (5-10%) expressed CD10 whereas the proportion of neoplastic PD1 þ cells was 440% in 6/10 cases (60% in this study). Chandra et al 28 and Dorfman et al 16 have also demonstrated the superior diagnostic utility of PD1 and CLX13 when compared to CD10 and Bcl-6.
The compartimentalization of the germinal centre, function and immunophenotype of T FH cells has been unknown until recently. Initial studies by AITL with hyperplastic follicles M Rodriguez-Justo et al hyperplastic germinal centres has also been seen after complete remission. 7 Interestingly, despite early involvement (pattern I) histologically, the majority of patients in all published series (Table  4) presented with clinical stages III/IV. All these findings suggest that progression from pattern I to II/ III is a histological evolution rather than a truly clinical progression of the disease as the majority of the patients had clinically advanced disease at diagnosis. It might also be possible that pattern I represents a variable degree of involvement of different lymph nodes at one time (ie limited involvement in pattern I vs more extensive in patterns II/III). Zhou et al 30 have shown an association among EBV, human herpesvirus (HHV) 6 and histological progression of Angioimmunoblastic T-cell lymphoma. EBV and HHV6 may play a role in the pathogenesis of this type of lymphoma and this might explain why some patients with Angioimmunoblastic T-cell lymphoma respond to antiviral therapy with valacyclovir. 31 Finally, some cases described as peripheral T-cell lymphomas with follicular pattern, 32 characterized by a follicular/perifollicular pattern and CD4 þ
CD8
À CD57 À Bcl6 þ CD10 þ immunophenotype might represent Angioimmunoblastic T-cell lymphoma pattern I. Recent studies using T FH cells markers have shown that a proportion of these cases derive from T FH cells and might be related to angioimmunoblastic T-cell lymphomas. 20, 33 Although the relationship between Angioimmunoblastic T-cell lymphoma and follicular PTCL-u merits further investigation, follicular PTCL remains as a variant of 'PTCL not otherwise specified' in the current WHO Lymphoma classification. 34 In summary, we have presented the clinical, morphological and immunophenotypical features of 10 cases of Angioimmunoblastic T-cell lymphoma using T FH cells markers in which current immunological studies and the presence of 'perifollicular' clusters of neoplastic cells raise the possibility that this tumour originates in the outer zone of the germinal centre. Our results also highlight the need to revise existing pathological criteria that are used to define Angioimmunoblastic T-cell lymphoma as the spectrum of this lymphoma may be broader than previously recognized and should include the recognition of the variant with hyperplastic germinal centres.
